drugset / Trial / NCT01992367
Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This is a single-centre, placebo-controlled, randomised, double-blind study to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of ASLAN003 in healthy subjects
Timeline
- Start
- 2013-08
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASLAN003 | Small molecule | — | — |
Indications
No indication recorded.